141 related articles for article (PubMed ID: 37787999)
41. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
42. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
[TBL] [Abstract][Full Text] [Related]
43. New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat.
Sloan AR; Thapliyal M; Lathia JD
Clin Cancer Res; 2024 Feb; 30(3):477-479. PubMed ID: 38038689
[TBL] [Abstract][Full Text] [Related]
44. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
[TBL] [Abstract][Full Text] [Related]
45. Selective Targeting of CD133-Expressing Glioblastoma Stem Cells Using Lentiviral Vectors.
Bayin NS; Placantonakis DG
Methods Mol Biol; 2018; 1741():91-101. PubMed ID: 29392693
[TBL] [Abstract][Full Text] [Related]
46. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells.
Li D; Hu Y; Jin Z; Zhai Y; Tan Y; Sun Y; Zhu S; Zhao C; Chen B; Zhu J; Chen Z; Chen S; Li J; Liu H
Leukemia; 2018 Sep; 32(9):2012-2016. PubMed ID: 30046161
[No Abstract] [Full Text] [Related]
47. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
48. Mesenchymal stem cell-like properties of CD133+ glioblastoma initiating cells.
Pavon LF; Sibov TT; de Oliveira DM; Marti LC; Cabral FR; de Souza JG; Boufleur P; Malheiros SM; de Paiva Neto MA; da Cruz EF; Chudzinski-Tavassi AM; Cavalheiro S
Oncotarget; 2016 Jun; 7(26):40546-40557. PubMed ID: 27244897
[TBL] [Abstract][Full Text] [Related]
49. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
50. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
51. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
52. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
[TBL] [Abstract][Full Text] [Related]
53. A compound chimeric antigen receptor strategy for targeting multiple myeloma.
Chen KH; Wada M; Pinz KG; Liu H; Shuai X; Chen X; Yan LE; Petrov JC; Salman H; Senzel L; Leung ELH; Jiang X; Ma Y
Leukemia; 2018 Feb; 32(2):402-412. PubMed ID: 28951562
[TBL] [Abstract][Full Text] [Related]
54. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
55. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
56. Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
Tchou J; Zhao Y; Levine BL; Zhang PJ; Davis MM; Melenhorst JJ; Kulikovskaya I; Brennan AL; Liu X; Lacey SF; Posey AD; Williams AD; So A; Conejo-Garcia JR; Plesa G; Young RM; McGettigan S; Campbell J; Pierce RH; Matro JM; DeMichele AM; Clark AS; Cooper LJ; Schuchter LM; Vonderheide RH; June CH
Cancer Immunol Res; 2017 Dec; 5(12):1152-1161. PubMed ID: 29109077
[TBL] [Abstract][Full Text] [Related]
57. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
58. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
Kim MP; Fleming JB; Wang H; Abbruzzese JL; Choi W; Kopetz S; McConkey DJ; Evans DB; Gallick GE
PLoS One; 2011; 6(6):e20636. PubMed ID: 21695188
[TBL] [Abstract][Full Text] [Related]
59. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
[TBL] [Abstract][Full Text] [Related]
60. A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
Tóth G; Szöllősi J; Abken H; Vereb G; Szöőr Á
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
